SOURCE: BioMedReports


September 07, 2011 07:01 ET

Report: Low Float, Vast Solid Pipeline and No Debt Make Ampio Attractive

LOS ANGELES, CA--(Marketwire - Sep 7, 2011) - The drugs in Colorado based Ampio Pharmaceuticals' (NASDAQ: AMPE) portfolio target huge markets.

According to a new report, there are a fairly wide number of drugs being developed by the company and considering its size, that is an impressive feat. Speculators are anticipating new information regarding all 7 of its products undergoing clinical trials in the short term, including anticipated business outlook and licensing agreements for Zertane in the EU and Asia.

Ampio Pharmaceuticals is potentially in a strong position with their pipeline, targeting huge drug markets while maintaining minimal costs.

Given the current market conditions, does this relatively undiscovered biotech's valuation hold potential for explosive growth?

The full exclusive report by Brian Wilson, including details about the company's pipeline and upcoming news catalysts, is available now at:

In addition, investors interested in accessing BioMedReports' new complete FDA Calendar and database of clinical trials and world-wide regulatory decisions which can be used to make more profitable trades during today's volatile markets can go to:

News developments and live healthcare sector updates are available constantly via twitter at:

About BioMedReports.Com
BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556